Latest News
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
31 March 2026 - Delonix Bioworks, a clinical-stage biotechnology company developing genetically engineered bacterial vaccines, announced on Monday the initiation of first-in-human (FIH) dosing in a Phase 1 clinical trial of DX-104.DX-104 is an innova...
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
31 March 2026 - Pharmaceutical company Hengrui Pharma and Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, on Monday reported results from a multi-centre...
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
31 March 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Monday that its US partner Ollin Biosciences has reported final, 20-week study completion data from its randomised, head-to-head Phase 1b JADE clinical...
Boston Scientific receives FDA clearance for Asurys fluid management system
...
Edwards Lifesciences reports positive two-year data for EVOQUE valve system
30 March 2026 - Structural heart innovation company Edwards Lifesciences (NYSE: EW) on Monday reported new two-year data from its TRISCEND II randomised trial demonstrating sustained clinical benefits for its EVOQUE transcatheter tricuspid valve repl...